CEO and Fund Manager, Renaissance Venture Capital Fund
Director, Life Sciences Institute, University of Michigan
Serial Entrepreneur and Investor
Founder, Gilt Groupe
Managing Partner at Pappas Ventures
Founder and CEO, Lighter Capital
VP of Research and Special Initiatives, Google
President & CEO, Indiana Biosciences Research Institute
GlaxoSmithKline has written Lexington, MA-based Synta Pharmaceuticals (NASDAQ: SNTA) a check for $80 million. The payment is the first installment under a cancer-drug development agreement that could ultimately be worth $1.1 billion for the Lexington firm.
Xconomy Insight · Special Report
Get advice from the experts to help your biotech startup succeed
Early-stage startups compete for the title of Startup of the Year
Consumer Technology Association (CTA)
Robust ecosystem supports tech hub and startup community
Wisconsin Economic Development Corporation
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
